Hylvastam (Sodium Hydrogen Carbonate)

Hylvastam is an intravenous buffering solution used in disorders of acid‑base balance and related emergency situations.

• Metabolic acidosis: restores normal blood pH by providing bicarbonate ions.
• Hyperkalemia: promotes intracellular shift of potassium, aiding in rapid potassium reduction.
• Cardiac arrest: used during resuscitation to counteract severe acidosis and improve myocardial function.

• Sodium Hydrogen Carbonate dissociates to release bicarbonate ions, which combine with excess hydrogen ions to form carbonic acid. Carbonic acid is then converted to CO₂ and water, which are eliminated via the lungs, thereby raising systemic pH and correcting metabolic acidosis. This alkalinizing effect also facilitates the movement of potassium into cells, helping to lower serum potassium levels.

Adverse reactions may occur with intravenous administration of Hylvastam.

Common Side Effects

• Injection site pain or irritation.
• Mild hypernatremia due to sodium load.
• Transient metabolic alkalosis.
• Fluid overload in patients with limited cardiac reserve.
• Mild hypotension from rapid infusion.
• Hypocalcemia secondary to alkalosis.

Serious or Rare Side Effects

• Severe metabolic alkalosis leading to respiratory depression.
• Pulmonary edema in volume‑overloaded patients.
• Cardiac arrhythmias from electrolyte shifts.
• Severe hypernatremia causing neurologic symptoms.
• Anaphylactic or severe hypersensitivity reactions.
• Intracranial hemorrhage in patients with rapid pH shifts.

Careful assessment and monitoring are required when using Hylvastam.

• Monitor serum electrolytes: check sodium, potassium, calcium, and bicarbonate levels before and after infusion.
• Assess acid‑base status: obtain arterial blood gas to guide dosing.
• Adjust dose in renal impairment: reduced clearance may increase risk of alkalosis.
• Use caution in heart failure or fluid‑overload states: limit infusion volume and rate.
• Avoid rapid bolus administration: infuse slowly to prevent sudden pH changes.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be evaluated prior to administration.

Major Interactions (Avoid)

• Calcium‑containing solutions: may precipitate and cause catheter blockage.
• Concurrent alkalinizing agents (e.g., other bicarbonate preparations): risk of severe metabolic alkalosis.
• Loop diuretics combined with high bicarbonate doses: can exacerbate electrolyte disturbances.

Moderate Interactions (Monitor Closely)

• NSAIDs: may reduce renal clearance of bicarbonate, increasing alkalosis risk.
• Potassium‑sparing diuretics: monitor potassium levels closely.
• Certain antibiotics (e.g., aminoglycosides): altered efficacy at high pH.
• ACE inhibitors or ARBs: may affect renal handling of sodium and bicarbonate.